

(12)

(21) 2 353 809

(51) Int. Cl. 7: **A61K 9/50, A61K 9/51**

(22) 07.12.1999

(85) 07.06.2001

(86) PCT/EP99/09545

(87) WO00/33820

(30) 198 56 432.5 DE 08.12.1998

(71) **BASF AKTIENGESELLSCHAFT,
D-67056, LUDWIGSHAFEN, XX (DE).**

**HEGER, ROBERT (DE).
BOHN, HERIBERT (DE).
BREITENBACH, JORG (DE).
AUWETER, HELMUT (DE).**

(72)

(74) **ROBIC**

(54) SYSTEMES NOYAU-COQUE NANOPARTICULAIRES ET LEUR UTILISATION DANS DES PREPARATIONS PHARMACEUTIQUES ET COSMETIQUES

(54) NANOPARTICULATE CORE-SHELL SYSTEMS AND USE THEREOF IN PHARMACEUTICAL AND COSMETIC PREPARATIONS

(57)

²²²Nanoparticulate preparations of pharmaceutical and cosmetic active substances ²with a core-shell structure, whereby the active substance is present in an X-²ray amorphous form, together with a polymer matrix and the shell consists of a ²stabilizing sheathing matrix.²



(86) **Date de dépôt PCT/PCT Filing Date:** 1999/12/07
(87) **Date publication PCT/PCT Publication Date:** 2000/06/15
(85) **Entrée phase nationale/National Entry:** 2001/06/07
(86) **N° demande PCT/PCT Application No.:** EP 99/09545
(87) **N° publication PCT/PCT Publication No.:** WO 00/33820
(30) **Priorité/Priority:** 1998/12/08 (198 56 432.5) DE

(51) **Cl.Int.⁷/Int.Cl.⁷** A61K 9/50, A61K 9/51

(71) **Demandeur/Applicant:**
BASF AKTIENGESELLSCHAFT, DE

(72) **Inventeurs/Inventors:**
BOHN, HERIBERT, DE;
BREITENBACH, JORG, DE;
AUWETER, HELMUT, DE;
HEGER, ROBERT, DE

(74) **Agent:** ROBIC

(54) **Titre : SYSTEMES NOYAU-COQUE NANOPARTICULAIRES ET LEUR UTILISATION DANS DES PREPARATIONS PHARMACEUTIQUES ET COSMETIQUES**

(54) **Title: NANOPARTICULATE CORE-SHELL SYSTEMS AND USE THEREOF IN PHARMACEUTICAL AND COSMETIC PREPARATIONS**

(57) **Abrégé/Abstract:**

Nanoparticulate preparations of pharmaceutical and cosmetic active substances with a core-shell structure, whereby the active substance is present in an X-ray amorphous form, together with a polymer matrix and the shell consists of a stabilizing sheathing matrix.



MEMO TO EXAMINER: √

INTERNATIONAL PRELIMINARY EXAMINATION REPORT TO FOLLOW: _____
(DO NOT ENTER VOLUNTARY AMENDMENTS BEFORE ART. 19 OR 34
AMENDMENTS ARE ENTERED)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT ENCLOSED:

Figure(s) _____ is/are defined but not illustrated.

Figure(s) ✓ _____ is/are illustrated but not defined.
Please verify.

Figure(s) _____ is /are improperly labelled.

Continuity of amended page(s) _____ in question.

Claim(s) _____ is/are cancelled.

Claim(s) _____ need to be renumbered.

Miscellaneous: _____

NANOPARTICULATE CORE-SHELL SYSTEMS AND USE THEREOF IN
PHARMACEUTICAL AND COSMETIC PREPARATIONS

The present invention relates to nanoparticulate preparations of pharmaceutical active ingredients with a core/shell structure, where the active ingredient is present in the core in X-ray amorphous form together with at least one polymer, and the shell consists of a polymeric coating matrix.

10 EP-A 425 892 discloses a method for improving the bioavailability of pharmaceutical active ingredients with peptide linkages, wherein a solution of the active ingredient in a water-miscible organic solvent is rapidly mixed with an aqueous colloid so that the active ingredient precipitates in colloidal form.

EP-A 276 735 describes active ingredient particles which are enveloped in a protective colloid and in which the active ingredient is dispersed in an oil phase. However, problems of compatibility frequently arise in oil phases.

20 EP-A-0169 discloses particulate pharmaceutical preparations of substances of low solubility in water, where the preparations are obtained by precipitating from a solution of the active ingredient after addition of a precipitating solution.

WO 93/10767 describes oral administration forms for peptide drugs in which the drug is incorporated in a gelatin matrix in such a way that the colloidal particles which form have a neutral charge. However, the disadvantage of such forms is their tendency to flocculate.

30 EP-A 0605 497 describes nanoparticles in which the active ingredient is stabilized in a lipid matrix. However, lipid matrices are unstable to shear forces, which may cause problems in further processing.

DE-A 4440337 describes the preparation of nanosuspensions stabilized with surfactants. However, in some circumstances, high surfactant concentrations are physiologically unacceptable.

40 US 5,145,684 and US 5,399,363 describe the preparation of crystalline nanoparticles by special grinding processes. However, the bioavailability from crystalline nanoparticles is generally relatively poor and they may, moreover, cause problems because of the polymorphism of some active ingredients.

0050/49619

2

US 4,826,689 describes a precipitation process in which amorphous spherical particles stabilized by no further addition or only small additions of surfactants are obtained. The shear stability of such systems and the possibility of sterilization are small.

5

EP-A 275,796 describes the preparation of colloidal dispersible systems with spherical particles below 500 nm in size and having a matrix structure, not a core/shell structure.

- 10 WO 97/14407 describes the preparation of nanoparticles by expansion from a solvent in a compressed gas, liquid or a supercritical fluid in the presence of an amphiphile.

- DE 3742 473 C2 describes hydrosols of solid particles of a
15 ciclosporin and a stabilizer which maintains the degree of dispersion of the particles. The particle size is in the colloidal range in these hydrosols. It is pointed out in particular that the described hydrosol particles consist of active ingredient mass.

20

- However, a disadvantage of these hydrosols is that the size of the hydrosol particles increases greatly over the course of time. This is particularly true when the dispersing phase of the hydrosol contains active ingredient solvent. It is obligatory to
25 employ this active ingredient solvent when preparing the hydrosol particles and it must then be removed as quickly as possible.

- The growth of hydrosol particles is attributable to what is called Ostwald ripening in which active ingredient molecules are
30 transported via the dispersing phase from small hydrosol particles to large hydrosol particles. This means that smaller particles slowly dissolve and larger particles slowly grow. Since the active ingredient ciclosporin has a slight residual solubility even in solvent-free water, it is not possible to
35 prevent the hydrosol particles growing even in that case.

- Concerning the stability of the nanoparticulate systems, the presence of the active ingredient in stable amorphous form and the wide applicability in a large number of pharmaceutical dosage
40 forms, however, there was still room for improvement.

It is an object of the present invention to find improved active ingredient-containing nanoparticulate preparations.

- 45 We have found that this object is achieved by the nanoparticulate preparations of pharmaceutical active ingredients which have a core/shell structure, where the active ingredient is present in

0050/49619

3

the core in X-ray amorphous form in a polymer matrix, and the shell consists of a stabilizing coating matrix of a polymer with protective colloid properties.

- 5 There are preferably at least two separate phases in the core, with one phase consisting of discrete, X-ray amorphous particles of the active ingredient, while the other phase is a molecular dispersion of the active ingredient in one or more polymers. The ratio of the amounts of core polymers to active ingredient
10 essentially determines whether the core is one phase or two phases.

- The decisive factor is that as the size of the active ingredient particles decreases the pressure on the substance to dissolve
15 increases. This results in an increased saturation solubility. The increased saturation solubility leads, according to Noyes-Whitney, to an increase in the rate of dissolution. An additional factor is that the bioactive substance is present in the formulations according to the invention in an energetically
20 unstable, metastable state. If the nanoparticle is insufficiently stabilized, this may lead in some cases to spontaneous crystallization, and the active ingredient precipitates out of the stabilized form.

- 25 The search was therefore also for solutions apart from a stable shell structure which also withstands procedures such as mixing into creams or ointments, homogenization in cosmetic preparations and the pressure and shear stresses during sterilization.

- 30 Surprisingly, the colloidal active ingredient preparations according to the invention show distinctly less growth of hydrosol particles than known active ingredient preparations which consist essentially exclusively of active ingredient mass in the core of the colloidal particles. One hour after the
35 aqueous hydrosols have been prepared in the presence of a solvent dissolving the active ingredient, the particle growth is a factor of 4 to 10 less. In the case of aqueous hydrosols which contain no solvent dissolving the active ingredient, the particle growth is reduced by a factor of 1.5 - 5.

40

- The colloidal particles present in the active ingredient preparation according to the invention have a polymer coating which envelops the core of the particles. The task of this polymer coating is to stabilize the particles in their colloidal
45 state so as to prevent heterogeneous particle growth (aggregation, flocculation etc.).

0050/49619

4

In addition, the colloidal particles present in the active ingredient preparation according to the invention have a core of active ingredient and polymer. The active ingredient in the interior of this core is present in X-ray amorphous form. It is essential that no crystalline active ingredient fractions are detectable (X-ray diffraction) in the active ingredient preparation. In particular, the polymers in the interior of the particles contribute to maintaining the active ingredient in its noncrystalline state and to stabilizing the colloidal structures in relation to homogeneous particle growth (Ostwald ripening).

Suitable polymeric stabilizers for the coating matrix of the shell according to the invention are swellable protective colloids such as, for example, bovine, porcine or fish gelatin, starch, dextrin, pectin, gum arabic, ligninsulfonates, chitosan, polystyrenesulfonate, alginates, casein, caseinate, methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, milk powder, dextran, whole milk or skim milk or mixtures of these protective colloids. Also suitable are homo- and copolymers based on the following monomers: ethylene oxide, propylene oxide, acrylic acid, maleic anhydride, lactic acid, N-vinylpyrrolidone, vinyl acetate, α - and β -aspartic acid. It is particularly preferred to use one of the gelatin types mentioned, in particular gelatin degraded with acid or base and having Bloom numbers in the range from 0 to 250, very particularly preferably gelatin A 100, A 200, B 100 and B 200, and low molecular weight, enzymatically degraded gelatin types with a Bloom number of 0 and molecular weights of from 15,000 to 25,000 D, such as, for example, Collagel A and Gelitasol P (supplied by Stoess, Eberbach) and mixtures of these gelatin types.

The preparations additionally contain low molecular weights of surface-active compounds. Particularly suitable as such are amphiphilic compounds or mixtures of such compounds. Suitable in principle are all surfactants with an HLB of from 5 to 20. Examples of suitable surface-active substances are: esters of long-chain fatty acids with ascorbic acid, mono- and diglycerides of fatty acids and their ethoxylation products, esters of mono-fatty acid glycerides with acetic acid, citric acid, lactic acid or diacetyltartaric acid, polyglycerol fatty acid esters such as, for example, the monostearate of triglycerol, sorbitan fatty acid esters, propylene glycol fatty acid esters, 2-(2-stearoyllactyl)lactic acid salts and lecithin. Ascorbyl palmitate is particularly preferably employed.

0050/49619

5

Suitable polymeric constituents present in the core of the particles of the active ingredient preparation according to the invention are in principle all polymers which are insoluble or only partly soluble in water or aqueous solutions or

- 5 water/solvent mixtures in a temperature range between 0 and 240°C, a pressure range between 1 and 100 bar, a pH range from 0 to 14 or ionic strengths up to 10 mol/l.

- Insoluble or only partly soluble means in this connection that
- 10 the second virial coefficient for the polymer(s) in water or a mixture of water and an organic solvent can assume values of less than zero (cf. M. D. Lechner, "Makromolekulare Chemie", Birkhäuser Verlag, Basle, pp. 170 - 175). The second virial coefficient, which provides information on the behavior of a
- 15 polymer in a solvent (mixture), can be determined experimentally, for example by light scattering measurement or determination of the osmotic pressure. The units of this coefficient are (mol-l)/g².

- 20 It is possible to employ one or more polymers. The molecular weights of the polymers used are in the range 1000 - 10,000,000 g/mol, preferably in the range 1000 - 1,000,000 g/mol. All polymers suitable for use in drugs and cosmetics are suitable in principle.

25

Polymers of particular interest are those which are soluble in water-miscible organic solvents, and insoluble or only partly soluble in water or aqueous solutions or water/solvent mixtures at temperatures between 0 and 240°C. The following polymers are

- 30 mentioned by way of example but without being limiting:

- Poly(vinyl ethers) such as, for example, poly(benzyloxyethylene), poly(vinyl acetals), poly(vinyl ketones), poly(allyl alcohol), poly(vinyl esters) such as, for example, poly(vinyl acetate),
- 35 poly(oxytetramethylene), poly(glutaraldehyde), poly(carbonates), poly(esters), poly(siloxanes), D,L-poly(lactide), poly(lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(amides), poly(piperazines), poly(anhydrides) such as, for example, poly(methacrylic anhydride), gutta percha, cellulose ethers such
- 40 as, for example, methylcellulose (degree of substitution 3 - 10%), ethylcellulose, butylcellulose, cellulose esters such as, for example, cellulose acetate or starches. In particular copolymers and block copolymers of the monomers of the above-mentioned polymers. In addition copolymers and block
- 45 copolymers of polyesters and hydroxy carboxylic acids and linear and star polyethylene glycol, for example AB and ABA block

0050/49619

6

copolymers of D,L-poly(lactide) and polyethylene glycol or poly(glycolide).

Also of particular interest are polymers which have an upper
 5 and/or lower miscibility limit at temperatures between 0 and 240°C
 in water or aqueous solutions or water/solvent mixtures, i.e.
 these polymers can be precipitated from corresponding solutions
 by raising or lowering the temperature. The following polymers
 are mentioned by way of example but without being limiting:

10

Poly(acrylamides), poly(methacrylamides) such as, for example,
 poly(N-isopropylacrylamide), poly(N,N-dimethylacrylamide),
 poly(N-(1,1-dimethyl-3-oxobutyl)acrylamide),
 poly(methoxyethylene), poly(vinyl alcohols), acetylated
 15 poly(vinyl alcohols), poly(oxyethylene), cellulose ethers such
 as, for example, methylcellulose (degree of substitution 20-40%),
 isopropylcellulose, cellulose esters, starches, modified starches
 such as, for example, methylether starch, gum arabic, and
 copolymers or block copolymers from monomers of the
 20 above-mentioned compounds. In particular AB or ABA block
 copolymers based on ethylene oxide and propylene oxide, e.g.
 poloxamers such as poloxamer 188 and poloxamer 407.

Also of particular interest are polymers which can be
 25 precipitated from corresponding solutions by altering the pH or
 the ionic strength at temperatures between 0 and 240°C in water or
 aqueous solutions or water/solvent mixtures. The following
 polymers are mentioned by way of example but without being
 limiting:

30

alginate, chitosan, chitin, shellac, polyelectrolytes,
 poly(acrylic acid), poly(methacrylic acid), poly(methacrylic
 esters) with secondary, tertiary or quaternary amino groups, in
 particular copolymers or block copolymers based on various
 35 acrylates, methacrylates, methacrylic acid, acrylic acid, e.g. a
 copolymer of methacrylic acid/methacrylic ester (MA/MAE ratio by
 weight 1:1 or 1:2) or a copolymer of dimethylaminoethyl
 methacrylate and methacrylic ester in the ratio 1:1 by weight
 (Eudragit® types).

40

The amounts of the various components are chosen according to the
 invention so that the preparations contain 0.1 to 70% by weight,
 preferably 1 to 40% by weight, of active ingredient, 1 to 80% by
 weight, preferably 10 to 60% by weight, of one or more polymeric
 45 stabilizers (coating polymer), 0.01 to 50% by weight, preferably
 0.1 to 30% by weight, of one or more polymers for the core, and 0
 to 50% by weight, preferably 0.5 to 10% by weight, of one or more

0050/49619

7

low molecular weight stabilizers. The percent by weight data are based on a dry powder.

In addition, the preparations may also contain antioxidants
5 and/or preservatives to protect the active ingredient. Examples of suitable antioxidants or preservatives are α -tocopherol, t-butylhydroxytoluene, t-butylhydroxyanisole, lecithin, ethoxyquin, methylparaben, propylparaben, sorbic acid, sodium benzoate or ascorbyl palmitate. The antioxidants or preservatives
10 may be present in amounts of from 0 to 10% of the total weight of the preparation.

The preparations may also contain plasticizers to increase stability of the final product. Examples of suitable plasticizers
15 are sugars and sugar alcohols such as sucrose, glucose, lactose, invert sugar, sorbitol, mannitol, xylitol or glycerol. Lactose is preferably employed as plasticizer. The plasticizers can be present in amounts of from 0 to 50% by weight.

20 Further pharmaceutical aids such as binders, disintegrants, flavorings, vitamins, colors, wetting agents, additions to influence the pH (cf. H. Sucker et al., Pharmazeutische Technologie, Thieme-Verlag, Stuttgart 1978) can likewise be introduced via the organic solvent or the aqueous phase.

25

To carry out the process according to the invention, firstly a solution of the active ingredient is prepared in a suitable solvent, with solution meaning in this connection a true
molecularly disperse solution or a melt emulsion. Depending on
30 the active ingredient, it is possible to employ temperatures of 0-250°C and pressures of up to 100 bar for this. Suitable solvents are organic, water-miscible solvents which are volatile and thermally stable and contain only carbon, hydrogen, oxygen, nitrogen and sulfur. They are expediently at least 10% by weight
35 miscible with water and have a boiling point below 200°C and/or have fewer than 10 carbon atoms. Appropriate alcohols, esters, ketones, ethers and acetals are preferred. Those particularly used are ethanol, n-propanol, isopropanol, butyl acetate, ethyl acetate, tetrahydrofuran, acetone, 1,2-propanediol 1-n-propyl
40 ether or 1,2-butanediol 1-methyl ether. Ethanol, isopropanol and acetone are very particularly preferred.

In one embodiment of the process, a molecularly disperse solution of the active ingredient in the chosen solvent is prepared
45 together with the polymer which is to be present in the active ingredient preparation in the core of the particles. This polymer

0050/49619

8

has the property of being insoluble or only partly soluble in water in a particular temperature, pH or salt range.

The concentration of the active ingredient/polymer solution prepared in this way is generally from 10 to 500 g of active ingredient per 1 kg of solvent and 0.01 to 400 g of polymer, with the polymer/active ingredient ratio by weight being between 0.01 to 1 and 5 to 1. In a preferred embodiment of the process, the low molecular weight stabilizer is added directly to the active ingredient/polymer solution.

In a process step following this, the active ingredient/polymer solution is mixed with an aqueous solution of the polymeric coating material. The concentration of the polymeric coating material is from 0.1 to 200 g/l, preferably 1 to 100 g/l.

In a further embodiment of the process, a molecularly disperse solution of the active ingredient in the chosen solvent is prepared without the polymer which is to be present in the active ingredient preparation in the core of the particles. The concentration of the active ingredient solution prepared in this way is generally from 10 to 500 g of active ingredient per 1 kg of solvent.

In a subsequent process step, this solution is mixed with an aqueous molecular solution of the polymer which is to be present in the active ingredient preparation in the core of the particles. The concentration of the polymer solution prepared in this way is generally from 0.01 to 400 g of polymer. The temperatures, pH values and salt concentrations of the two solutions which are to be combined are chosen so that the active ingredient and the polymer are insoluble after the solutions have been combined. In a preferred embodiment of the process, the low molecular weight stabilizer is added directly to the active ingredient solution.

In a process step following this, the active ingredient/polymer precipitate is mixed with an aqueous solution of the polymeric coating material. The concentration of the polymeric coating material is from 0.1 to 200 g/l, preferably 1 to 100 g/l.

In order to minimize the size of the particles obtained in the mixing process, it is advisable for the mechanical energy input during mixing of the ciclosporin solution with the solution of the coating material to be high. Such an energy input is possible, for example, by vigorous stirring or shaking in a suitable apparatus, or by spraying the two components in a

0050/49619

9

compact jet into a mixing chamber so that vigorous mixing takes place.

The mixing process can be carried out batchwise or, preferably, continuously. The mixing process results in precipitation. The resulting suspension or colloid can then be converted in a manner known per se into a dry powder, for example by spray drying, freeze drying or fluidized bed drying.

- 10 The conditions to be chosen in the specific case in relation to varying the water/organic solvent system, the pH values, the temperatures or the ionic strengths when carrying out the process according to the invention can be established by the skilled worker by a few simple preliminary tests on the appropriate
15 polymer with the aid of the second virial coefficient.

The initial dispersion can then be subjected to drying processes known to the skilled worker.

- 20 Accordingly, the nanoparticulate systems according to the invention can, after the preparation, also be dried, for example by spray drying or lyophilization, and then redispersed again with virtually the same particle size distribution. This is a great advantage for all applications in which the preparation
25 must be stored for as long as possible, is exposed to extreme stresses such as heat or cold, or is to be transferred from an aqueous carrier into other carriers as solvents. This means that the preparations according to the invention are no longer bound to the solvent with which they were prepared.
- 30 On lyophilization of the nanoparticles according to the invention, it is possible to add cryoprotective substances such as, for example, trehalose or polyvinylpyrrolidones.

- It is thus possible to obtain according to the invention dry
35 powders which do not lose the properties they acquired in the initial dispersion. This means that the amorphous nature of the active ingredient and core/shell structure are retained. It is a further property according to the invention that, on redissolving, these dispersions have the same particle size
40 distribution, with a variation of 20%, preferably < 15%, which they had as initial dispersion.

- The interfacial tension of the nanoparticulate dispersions according to the invention is 20 - 40 mN/m, preferably 10 -
45 30 nM/m.

0050/49619

10

The particle sizes of the core/shell structures are in the range from 0.01 to 2 μm , preferably 0.05 to 0.9 μm .

Active ingredients of low solubility according to the invention
5 particularly preferably have a solubility of less than 10 mg/ml of water at 25°C.

Examples of suitable active ingredients are:

- 10 - analgesics/antirheumatics such as codeine, diclofenac, fentanyl, hydromorphone, ibuprofen, indomethacin, levomethadone, morphine, naproxen, piritramide, piroxicam, tramadol
- 15 - antiallergics such as astemizole, dimetindene, doxylamine, loratadine, meclozine, pheniramine, terfenadine
- antibiotics/chemotherapeutics such as erythromycin, framycetin, fusidic acid, rifampicine, tetracycline,
20 thiacetazone, tyrothricin
- antiepileptics such as carbamazepine, clonazepam, mesuximide, phenytoin, valproic acid
- 25 - antimycotics such as clotrimazole, fluconazole, itraconazole
- calcium channel blockers such as darodipine, isradipine
- corticoids such as aldosterone, betametasone, budesonide,
30 dexametasone, fluocortolone, fludrocortisone, hydroxycortisone, methylprednisolone, prednisolone
- hypnotics/sedatives
benzodiazepines, cyclobarbitol, methaqualone, phenobarbital
35
- immunosuppressants
azathioprine, ciclosporin
- local anesthetics
40 benzocaine, butanilacaine, etidocaine, lidocaine, oxybuprocaine, tetracaine
- migraine remedies
dihydroergotamine, ergotamine, lisuride, methysergide
45

0050/49619

11

- anesthetics
droperidol, etomidate, fentanyl, ketamine, methohexital,
propofol, thiopental
- 5 - ophthalmologicals
acetazolamide, betaxolol, bupranolol, carbachol, carteolol,
cyclo-drine, cyclopentolate, diclofenamide, edoxudine,
homatropine, levobunolol, pholedrine, pindolol, timolol,
tropicamide
- 10 - phytopharmaceuticals
hypericum, urtica folia, artichoke, Agnus castus, cimicifuga,
devil's claw, broom, peppermint oil, eucalyptus, celandine,
ivy, kava-kava, echinacea, valerian, palmetto extract, milk
15 thistle, Ginkgo biloba, Aloe barbadensis, Allium sativum,
Panax ginseng, Serenoa repens, Hydrastis canadensis,
Vaccinium macrocarpon or mixtures thereof
- protease inhibitors
20 e.g. saquinavir, indinavir, ritonavir, nelfinavir, palinavir
or combinations of these protease inhibitors
- sex hormones and their antagonists
anabolics, androgens, antiandrogens, estradiols, gestagens,
25 progesterone, estrogens, antiestrogens such as tamoxifen
- vitamins/antioxidants such as carotenoids or carotenoid
analogs, for example β -carotene, canthaxanthin, astaxanthin,
lycopene or lipoic acid
30
- cytostatics/antimetastatics
busulfan, carmustine, chlorambucil, cyclophosphamide,
dacarbazine, dactinomycin, estramustine, etoposide,
fluorouracil, ifosfamide, methotrexate, paclitaxel,
35 vinblastine, vincristine, vindesine.

The nanoparticulate preparations according to the invention are
suitable in principle for producing all pharmaceutical dosage
forms: oral drug forms, topical drug forms such as

- 40 dermatologicals, ophthalmologicals, pulmonary or nasal forms,
buccal forms, anal or intravaginal forms, enteral and parenteral
forms.

- It is thus possible to process the preparations according to the
45 invention to tablets, pellets, sachets, drinkable formulations,
suppositories, injection solutions or capsule fillings.

0050/49619

12

Thus, for example, formulation in soft or hard gelatin preparations is possible. Formulations of these types then represent examples of multiparticulate systems in which the nanoparticles which is one phase the preparation of the soft
5 gelatin matrix is another phase which, moreover, may contain another or the same active ingredient.

In the same way, the systems according to the invention can also be introduced into other matrices and, in this case, represent a
10 separate phase from the remaining matrix. Matrices of this type may be tablets, suppositories or systems for pulmonary administration or transdermal administration.

In connection with amorphous active ingredient embedding, mention
15 must also be made of a particular property of active ingredients, polymorphism. Many active ingredients exist in more than one crystalline form. It can generally be assumed that more than 50% of all active ingredients exist in several crystalline forms. All these polymorphic modifications of an active ingredient are
20 chemically identical but have different physical properties such as melting point, density and solubility. This means that the different modifications also have an effect on the processability and, in the most critical case, also on the bioavailability.

25 The preparations according to the invention make it possible in a simple manner to convert active ingredients into the amorphous state and can use as starting materials also products of widely varying particle size distribution as well as amorphous bulk materials, and thus avoid the problem of different polymorphic
30 forms and the possible disadvantages associated therewith relating to solubility, storage stability and bioavailability.

It was also an object of the present invention to find novel formulations for the nanoparticulate amorphous core/shell
35 structures. It was surprisingly possible, after adaptation of the polymeric stabilizers employed, to meet the requirements for injectable products, to obtain stable core/shell structures also with gelatin hydrolyzates. The advantage of using such gelatin hydrolyzates is that the histamine response in vivo on
40 administration as intravenous, intramuscular or subcutaneous administration is distinctly less.

The nanoparticles according to the invention make aseptic preparation and sterile filtration possible.

0050/49619

13

Since solid tumors have the ability to filter particles out of the bloodstream, the preparations according to the invention are suitable for achieving tumor targeting. It is thus possible to achieve locally highly concentrated accumulations of cytotoxic substances. This means that therapy of cancers by the nanoparticulate systems according to the invention is particularly preferred.

Cytostatics suitable and preferred for the technology according to the invention are taxols such as paclitaxel, cis-platin, but also non-intercalating farnesyltransferase inhibitors.

It is further known that nanoparticulate systems are able to overcome the blood-brain barrier and thus can be employed, in particular, in the area of therapy of CNS disorders. The same also applies to the nanoparticles according to the invention, which are thus also suitable in particular for use for treatments of disorders in the area of the CNS.

Although the polymer weight is distinctly lower than in the forms described in EP-A 425 892, it is possible to obtain stable products which are adapted to requirements. The small number of ancillary substances is an advantage compared with other processes. The preparations according to the invention of the amorphous core/shell nanoparticles often consist only of the polymeric carrier and the bioactive substance.

The amorphous core/shell nanoparticles according to the invention have another advantage because of the process. The vigorous mixing of the bioactive substance from a solvent into a non-solvent makes it possible to introduce small amounts of the polymer, which later aggregates by adsorption onto the surface during the formation of the spherical structure, into the matrix. This contributes to stabilizing the amorphous and thus metastable state. It specifically comprises a multiphase system with an outer shell composed of the polymeric addition responsible for the dispersion, and of an amorphous structure which contains, still dissolved, the same polymeric addition or another addition as crystallization inhibitor.

A special situation is the occurrence of liquid crystalline systems in the amorphous phase of the preparations according to the invention.

Preparations of low molecular weight peptides such as, for example, LMWH make administration possible by the oral route and, advantageously, with an identical formulation as injection, the

0050/49619

14

administration route which is at present employed as standard for deep vein thrombosis.

In general, it can be stated that the preparations according to
5 the invention can be employed advantageously in virtually all administration forms based on only a single formulation.

The preparations according to the invention are also suitable for colon targeting.

10

It is likewise possible according to the invention to obtain injectable depot products.

The preparations according to the invention can also be employed
15 in parenteral alimentation. In this connection the preparation according to the invention can be used in particular for formulating vitamins and amino acids.

In nicotine replacement therapy it is possible with the
20 preparations according to the invention, e.g. with nicotine tartrate or nicotine base, to achieve the necessary plasma peaks which are particularly important in the cessation process.

Topical application for hair growth active ingredients such as
25 minoxidil is also advantageous with the preparation according to the invention. The hair follicles can be reached better because of the structure.

In the pulmonary administration of the preparations according to
30 the invention, apart from the administration of asthma therapeutics such as budesonide and cytostatics, in particular the administration of protein and peptide therapeutics is contemplated. Examples are vasopressin analog, LHRH antagonists, glucagon, parathyroid hormone, calcitonin, insulin, LHRH analog
35 leuprolide, granulocyte colony stimulating factor and somatropin.

Administration is possible not only as powder but also as atomized aqueous suspension. Administration can take place through the nose, bronchi or lung. For nasal administration it is
40 particularly advantageous to choose an aqueous suspension because in this way irritation of the nasal mucous membranes and a stinging sensation due to organic solvents is avoided.

The active ingredient class of leukotriene antagonists is
45 particularly suitable as area of use for the technology.

0050/49619

15

The preparations according to the invention can also be used for converting antisense active ingredients, that is to say oligonucleotides with a complementary base sequence to messenger RNA, into formulations which can be administered. The

5 phosphorothioate oligonucleotides are preferred. It is moreover possible to use, besides local injection, also subcutaneous or intravenous administration as infusion or injection, and oral administration. However, dermal administration and inhalation are also conceivable.

10

The forms according to the invention can be employed in oral forms which can be used both from preparations in conventional tablets and in capsules. This area of application is opened up in particular by the possibility of also being able to produce

15 suppository formulations, which is ensured by the stability of the nanoparticles according to the invention on stirring into the carrier matrices. It is advantageous in this connection that on rectal administration only a limited liquid volume is available, and the preparations according to the invention can be dispersed
20 extremely well in the small liquid volume and be absorbed.

The advantageousness of the forms according to the invention can be generally stated in the following points:

- 25 • greater relative bioavailability
• smaller food effect
• less variability.

Since it is also possible to use acrylates, lectins, caseinates,
30 gelatins, chitosans, hyaluronic acids or mussel adhesion protein as shell polymers, it is also possible to produce mucoadhesive preparations with a nanoparticulate size.

The increased adhesiveness of nanoparticulate preparations may
35 eventually also result in an increase in the bioavailability. This may be of interest in particular on nasal administration. An additional factor is that the adhesiveness of the nanoparticles to the nasal mucosa has a beneficial effect on the residence time, which otherwise tends to be too short, and may thus
40 contribute to increasing the bioavailability.

The preparations according to the invention can also be employed on the eye. Especially in gel systems which react with an increase in viscosity at body temperature, the nanoparticulate
45 systems according to the invention form a separate phase which is able to lead the active ingredient in nanoparticulate amorphous

0050/49619

16

form to the eye and is homogeneously dispersed during the gel formation in the matrix.

It is likewise possible to produce contrast agents for medical
5 diagnostic imaging such as X-ray methods, scintigraphy, ultrasound, magnetic resonance imaging, fluorescence angiography and ophthalmology using the preparations according to the invention.

10 In cosmetics and dermatologicals it is possible to employ the core/shell nanoparticles according to the invention for protecting hydrolysis-sensitive active ingredients. In addition, preparations of this type are able, because of the small particle size, to facilitate penetration between the stratum corneum
15 cells. In the cosmetics sector, the preparations according to the invention can be used in the formulation of perfumes and decorative cosmetics such as, for example, the incorporation of dyes or pigments into lipsticks, eyeliners, eyeshadows or nail varnishes. The preparations can also be employed in creams, gels
20 and ointments.

A particular advantage of the nanoparticulate preparations according to the invention is that only a few ancillary substances are required. Apart from the polymeric coating matrix
25 and the matrix polymers in the core, it is possible substantially to dispense with other surface-active ancillary substances.

Preparation example 1

30 Preparation of a ritonavir dry powder with an active ingredient content in the region of 20% by weight

a) Preparation of the micronizate

35 3 g of ritonavir were stirred into a solution of 0.6 g of ascorbyl palmitate and 0.6 g of a copolymer of ethyl acrylate and methacrylic acid (1:1), (Kollicoat[®] MAE, BASF AG) in 36 g of isopropanol at 25°C, resulting in a cloudy suspension.

40 To convert the ritonavir and the Kollicoat into the form of a molecular dispersion, this coarse dispersion was mixed with 120 g of water at a mixing temperature of 200°C for 0.3 s. To precipitate the ritonavir and the Kollicoat in colloidal form, this molecularly disperse solution was fed into another mixing
45 chamber. There it was mixed with 490 g of an aqueous solution of 4.3 g of gelatin A 100 and 6.5 g of lactose in deionized water, which had been adjusted to pH = 9.0 with 1 N NaOH, at 25°C. The

0050/49619

17

pressure throughout the process was limited to 30 bar. After mixing, a colloidal ritonavir dispersion was obtained with a cloudy yellowish color.

5 Quasi-elastic light scattering was used to determine the average particle size as 260 nm with a variance of 42%. The average particle size increased by only 20 nm to 280 nm over the course of one hour. A colloidal ritonavir dispersion prepared analogously without Kollicoat shows an increase in the particle
10 size by 400 nm over the course of one hour. These facts are summarized in Table 1.

Table 1

15	Time after preparation of the colloidal dispersion	Colloidal dispersion with Kollicoat	Colloidal dispersion without Kollicoat
	3 min	260 nm	410 nm
	15 min	259 nm	485 nm
20	30 min	258 nm	671 nm
	60 min	281 nm	835 nm

b) Drying of dispersion a) to give a nanoparticulate dry powder

25 Spray drying of the product 1a) afforded a nanoparticulate dry powder. The active ingredient content in the powder was determined by chromatography to be 19.84% by weight. The dry powder dissolves in drinking water to form a cloudy yellowish dispersion (hydrosol) with an average particle size of 306 nm
30 with a variance of 48%. The average particle size increased by only about 30 nm to 349 nm over the course of one hour. A colloidal ritonavir dispersion prepared analogously without Kollicoat shows an increase in the particle size by about 350 nm over the course of one hour. These facts are summarized in
35 Table 2.

Table 2

40	Time after preparation of the colloidal dispersion	Colloidal dispersion with Kollicoat	Colloidal dispersion without Kollicoat
	3 min	306 nm	585 nm
	15 min	307 nm	726 nm
	30 min	324 nm	815 nm
45	60 min	349 nm	938 nm

0050/49619

18

c) Wide-angle X-ray scattering

The scattering plots for active ingredient (top) and dry powder from 1b) (bottom) are depicted in Figure 1. The ritonavir starting material is crystalline, as proven by the X-ray diagram which is characterized by a number of sharp interferences. In contrast thereto, the scattering plot for the dry powder shows only diffuse, broad interference maxima which are typical of an amorphous material. The active ingredient is accordingly in X-ray amorphous form in the dry powder prepared as in 1b). This also applies to the ancillary substances lactose and ascorbyl palmitate which are otherwise crystalline.

Preparation example 2

15

Preparation of a ciclosporin dry powder with an active ingredient content in the region of 20% by weight

a) Preparation of the micronizate

20

3 g of ciclosporin were stirred into a solution of 0.6 g of ascorbyl palmitate and 0.6 g of Kollicoat® MAE (BASF AG) in 36 g of isopropanol at 25°C, resulting in a slightly cloudy suspension.

25 To convert the ciclosporin A and the Kollicoat into the form of a molecular dispersion, this coarse dispersion was mixed with 120 g of water at a mixing temperature of 200°C for 0.3 s. To precipitate the ciclosporin and the Kollicoat in colloidal form, this molecularly disperse solution was fed into another mixing chamber. There it was mixed with 490 g of an aqueous solution of 4.3 g of gelatin A 100 and 6.5 g of lactose in deionized water, which had been adjusted to pH = 9.0 with 1 N NaOH, at 25°C. The pressure throughout the process was limited to 30 bar. After mixing, a colloidal ciclosporin A dispersion was obtained with a cloudy white color.

Quasielastic light scattering was used to determine the average particle size as 249 nm with a variance of 42%. The average particle size did not increase within the accuracy of measurement over the course of one hour. A colloidal ciclosporin dispersion prepared analogously without kollicoat shows an increase in the particle size by 250 nm over the course of one hour. These facts are summarized in Table 3.

45

0050/49619

19

Table 3

5	Time after preparation of the colloidal dispersion	Colloidal dispersion with Kollicoat	Colloidal dispersion without Kollicoat
	3 min	249 nm	330 nm
	15 min	257 nm	364 nm
	30 min	251 nm	410 nm
	60 min	248 nm	580 nm

10

b) Drying of dispersion a) to give a nanoparticulate dry powder

Spray drying of the product 2a) afforded a nanoparticulate dry powder. The active ingredient content in the powder was

15 determined by chromatography to be 20.03% by weight. The dry powder dissolves in drinking water to form a cloudy white dispersion (hydrosol) with an average particle size of 263 nm with a variance of 48%. The average particle size did not increase within the accuracy of measurement over the course of

20 one hour. A colloidal ciclosporin dispersion prepared analogously without Kollicoat shows an increase in the particle size by about 150 nm over the course of one hour. These facts are summarized in Table 4.

25 Table 4

30	Time after preparation of the colloidal dispersion	Colloidal dispersion with Kollicoat	Colloidal dispersion without Kollicoat
	3 min	263 nm	435 nm
	15 min	259 nm	463 nm
	30 min	264 nm	518 nm
	60 min	267 nm	575 nm

35 Preparation example 3

A micronizate containing propafenone as active ingredient was prepared in analogy to example 1.

40 Preparation example 4

A micronizate which, in place of the polymer Kollicoat[®] MAE, contained as polymer a poly(D,L-lactide-co-glycolide) (49 mol% D,L-lactide, 51 mol% glycolide) was prepared in analogy to

45 example 2.

0050/49619

20

Preparation example 5

Preparation of a canthaxanthin dry powder with an active ingredient content in the region of 5%.

5

a) Preparation of the micronizate

15 g of canthaxanthin were stirred into a solution of 6 g of ethoxyquin and 45 g of Kollicoat MAE in 400 g of tetrahydrofuran
10 at 25°C, resulting in a cloudy suspension.

To convert the canthaxanthin into the form of a molecular dispersion, this coarse dispersion was pumped at a flow rate of 1.8 kg/h through a heat exchanger and thereby heated to a
15 temperature of 161.5°C. To precipitate the canthaxanthin and the Kollicoat in colloidal form, this molecularly disperse solution was fed, 1.4 seconds after reaching the temperature of 161.5°C, into another mixing chamber. There it was mixed with 9 600 g of an aqueous solution of 30 g of gelatin B 200 and 25 g of sucrose
20 in deionized water, which had been adjusted to pH = 11.8 with 1 N NaOH, at 25°C. The pressure throughout the process was limited to 60 bar. After mixing, a colloidal canthaxanthin dispersion was obtained with a cloudy reddish color.

25 Quasi-elastic light scattering was used to determine the average particle size as 796 nm with a variance of 81%.

b) Drying of dispersion a) to give a nanoparticulate dry powder

30 Working up in a rotary evaporator and subsequent spray drying of the product 1a) afforded a nanoparticulate dry powder. The active ingredient content in the powder was determined by UV/VIS spectroscopy to be 5.75% by weight. The dry powder dissolves in water at pH values > 7 to form a cloudy reddish dispersion
35 (hydrosol) with an average particle size of 722 nm with a variance of 43%.

Preparation example 6

40 Preparation of an astaxanthin dry powder with an active ingredient content in the region of 25% by weight

a) Preparation of the micronizate

45 1 g of astaxanthin was stirred into a solution of 3 g of a methacrylic acid/methyl methacrylate copolymer in the ratio 1:1 (Eudragit L 100, Röhm GmbH) in 200 g of tetrahydrofuran at 25°C.

0050/49619

21

To convert the astaxanthin into the form of a molecular dispersion, this dispersion was pumped at a flow rate of 1.8 kg/h through a heat exchanger and thereby heated to a temperature of 73°C. To precipitate the astaxanthin and the Eudragit L 100 in
 5 colloidal form, this molecularly disperse solution was fed into another mixing chamber. There it was mixed with 10 000 g of deionized water at 25°C. The pressure throughout the process was limited to 30 bar. After the mixing, a colloidal astaxanthin dispersion was obtained with a reddish color.

10

Quasi-elastic light scattering was used to determine the average particle size as 256 nm with a variance of 56%.

b) Drying of dispersion a) to give a nanoparticulate dry powder

15

Working up in a rotary evaporator and subsequent spray drying of the product 1a) afforded a nanoparticulate dry powder. The active ingredient content in the powder was determined by UV/VIS spectroscopy to be 24.3% by weight. The dry powder dissolves in
 20 alkaline water to form a red dispersion (hydrosol) with an average particle size of 273 nm with a variance of 53%.

Preparation example 7

25 Preparation of an astaxanthin dry powder with an active ingredient content in the region of 25% by weight

a) Preparation of the micronizate

30 2 g of astaxanthin were stirred into a solution of 6 g of Eudragit L 100 (Röhm GmbH) in 200 g of tetrahydrofuran at 25°C. To convert the astaxanthin into the form of a molecular dispersion, this dispersion was pumped at a flow rate of 2.0 kg/h through a heat exchanger and thereby heated to a temperature of 73°C. To
 35 precipitate the astaxanthin and the Eudragit L 100 in colloidal form, this molecularly disperse solution was fed into another mixing chamber. There it was mixed with 10 000 g of deionized water at 25°C. The pressure throughout the process was limited to 30 bar. After mixing, a colloidal astaxanthin dispersion was
 40 obtained with a reddish color.

Quasi-elastic light scattering was used to determine the average particle size as 178 nm with a variance of 22%.

45

0050/49619

22

b) Drying of dispersion a) to give a nanoparticulate dry powder

Working up in a rotary evaporator and subsequent spray drying of the product 1a) afforded a nanoparticulate dry powder. The active ingredient content in this powder was determined by UV/VIS spectroscopy to be 22.7% by weight. The dry powder dissolves in alkaline water to form a cloudy reddish dispersion (Hydrosol) with an average particle size of 175 nm with a variance of 25%.

10 The nanoparticles according to the invention can be used, for example, to produce the following dosage forms:

1. Tablet

15 10% by weight of the nanoparticulate preparation (on lactose as carrier) are mixed with 10% by weight of sucrose, 28% by weight of microcrystalline cellulose, 3% by weight of Kollidon VA 64 and 0.2% by weight of Aerosil and then directly compressed. The tablet weight is 250 mg. The diameter is 8 mm. The hardness 20 150 N, the disintegration in water 13 min.

2. Patch

A patch with a reservoir of 17.5% by weight of polystyrene and 25 17.5% by weight of polyvinylacetate and 30% by weight of the nanoparticles according to the invention was produced.

3. Oil-in-water cream

30 24 g of liquid paraffin, 5 g of Cremophor S 9 (polyethylene glycol stearate), 6 g of beeswax, 2 g of Cutina CP (cetyl palmitate), 3 g of glycerol and 60 g of water form the basis of the cream into which 20 g of the nanoparticulate preparation according to the invention are stirred.

35

For fabrication, Cremophor is dissolved in the lipid phase and this mixture is mixed with water with vigorous stirring. Stirring is continued until cold, and then the nanoparticulate preparation is added and homogenized.

40

4. Formulation for topical use

A preparation for topical use with the nanoparticulate core/shell preparations was obtained as follows: (in g/100g)

45

0050/49619

23

0.14 g of methylparaben and 0.1 g of propylparaben plus 0.1 g of EDTA dihydrate are dissolved in 78.42 g of water at 80°C. After being allowed to cool to about 30°C, 20 g of the nanoparticles according to the invention are added as powder and homogenized by 5 stirring. Subsequently 0.8 g of Carbomer 934 P and 0.44 g of NaOH are added.

5. Gel

10 Propylene glycol 20 g, poloxamer 188 5 g, poloxamer 407 22 g, NaCl 1 g, water 51 g, micronize from example 1 20 g.

6. Eye drops

15 10 g of micronize from example 1, 14 g of Kollidon K 25, preservative as required, water ad 100 g.

7. Aerosol

20

Preparation of a powder formulation from:

a nanoparticulate formulation with 75 mg of budesonide, to an aqueous colloidal suspension of which 1400 g of lactose are added. The mixture is then spray-dried. The particle size of the 25 resulting powder is 7 µm, the moisture content is 0.8% by weight.

Preparation with propellant:

0.25% by weight of a nanoparticulate budesonide preparation is 30 introduced with a mixture of 4% by weight of ethanol and water (50:50) and 95.75% by weight of 1,1,1,2-tetrafluoroethane into an aluminum vessel under pressure.

8. Plaster

35

7% by weight of glycol are added to a mixture of 6% by weight of polyacrylic acid and 5% by weight of sodium polyacrylate plus 0.5% by weight of Aerosil 200. This mixture is homogenized by stirring. The mixture is then added to a solution of 0.03% by 40 weight of EDTA in 65% by weight of water. To this is further added 0.3% by weight of polyoxyethylene sorbitan monostearate with heating to 50°C. Finally, the nanoparticulate powder according to the invention is stirred into the mixture, and the composition is applied to a nonwoven plaster base.

45

0050/49619

24

9. Injectable depot gel

10% by weight of the nanoparticles according to the invention,
30% by weight of a lactic acid/glycol copolymer, 10% by weight of
5 ethanol, 50% by weight of isotonic saline

10. Effervescent tablet

217 g of propafenone micronizate from preparation example 3
10 200 g of potassium bicarbonate
205.7 g of citric acid
142.1 g of instant sugar
32.0 g of Macrogol 200
2 g of lemon flavor
15 1.2 g of saccharin

The mixture was compressed under conventional conditions to a
tablet with a thickness of 5.9 mm and a weight of 2.9 g.
Disintegration in water (beaker): 9 min.

20

25

30

35

40

45

0050/49619

25

We claim:

1. A nanoparticulate preparation of a pharmaceutical or cosmetic
5 active ingredient with a core/shell structure, in which the
X-ray amorphous active ingredient is present in the core
together with one or more polymers, and the shell consists of
a stabilizing coating matrix.
- 10 2. A preparation as claimed in claim 1, in which the core has at
least two separate phases, one phase consisting of amorphous
particles of the active ingredient, and the other phase being
a molecular dispersion of the active ingredient in a polymer
matrix.
- 15 3. A preparation as claimed in claim 1, in which the core has at
least two separate phases, one phase consisting of amorphous
active ingredient, and the other phase being a polymer matrix
free of active ingredient.
- 20 4. A preparation as claimed in claim 1 or 2, wherein the core
polymers are polymers which are suitable for pharmaceutical
and cosmetic applications and which are insoluble or only
partly soluble in water.
- 25 5. A preparation as claimed in any of claims 1 to 4, comprising
polymeric peptides as coating matrix.
6. A preparation comprising gelatin as coating polymer.
- 30 7. A preparation as claimed in any of claims 1 to 5, comprising
casein or sodium caseinate as coating matrix.
8. A preparation as claimed in any of claims 1 to 7, in which
35 the core/shell structures have an average particle diameter
between 0.01 and 2 μm .
9. A hydrosol of a preparation as claimed in any of claims 1-8.
- 40 10. A hydrosol as claimed in claim 9, in which the sizes of the
hydrosol nanoparticles increase by less than 50% in the first
hour after preparation of the hydrosol.

45

Drawing

0050/49619

26

11. A process for producing preparations as claimed in any of
claims 1 to 4, which comprises preparing a solution of the
active ingredient in an organic solvent which is at least 10%
by weight miscible with water, mixing this solution with the
core polymer or a solution of the core polymer in an organic
solvent, and bringing the resulting mixture into contact with
an aqueous solution of the coating polymer.
12. A process as claimed in claim 11, wherein a precipitation of
core particles takes place on mixing the active ingredient
solution with the solution of the core polymers.
13. A process as claimed in claim 11 or 12, wherein the second
virial coefficient for the core polymers assumes a value
below zero on mixing with the solution of the active
ingredient.
14. The use of a preparation as claimed in any of claims 1 to 7
for producing pharmaceutical and cosmetic presentations.

WO 00/33820

PCT/EP99/09545

1/1

Ritonavir

Fig. 1

